Dan T. Vogl

Hematology

3400 Civic Center Boulevard
West Pavilion, 4th Floor
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 96 publications

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Journal: Transplantation and cellular therapy

Published: February 12, 2026

Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.

Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 11, 2026

The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target.

The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

Outcomes of relapse after teclistamab therapy in multiple myeloma.

Outcomes of relapse after teclistamab therapy in multiple myeloma.

Journal: Blood cancer journal

Published: August 14, 2025

Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma.

Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma.

Journal: Blood advances

Published: July 31, 2025

Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma.

Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma.

Journal: Blood advances

Published: July 31, 2025

Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma.

Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma.

Journal: Blood advances

Published: July 31, 2025

Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series.

Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series.

Journal: Blood cancer journal

Published: July 30, 2025

NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.

NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: May 09, 2025

CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy.

CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy.

Journal: Nature medicine

Published: March 25, 2025

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma.

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma.

Journal: Blood

Published: January 23, 2025

A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma.

A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 10, 2024

Showing 1-12 of 96

Last Updated: 09/26/2026